In 2017, a Work Group was assembled to conduct a systematic review of 3HP regimen studies published between January 2006 to June 2017, specifically looking at outcomes in children, individuals with HIV/AIDS, and those who self-administered treatment.
The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.
Control of active tuberculosis (TB) and a major effort to decrease latent TB infection are both necessary to reduce morbidity and achieve TB elimination in the United States.
Researchers developed an algorithmic approach to diagnosing lung cavitary diseases.
Bedaquiline and delamanid were effective and well tolerated in patients with multidrug-resistant tuberculosis.
Large cavitary lung disease may increase cough frequency that lasts for a longer duration in individuals with tuberculosis.
HIV-positive patients with pulmonary tuberculosis benefited from daily antituberculosis therapy in terms of effectiveness and rifampicin resistance.
Shorter treatment regimens for tuberculosis were associated with increased completion rates and fewer adverse events compared with traditional regimens.
Patients with type 2 diabetes treated with sulfonylureas had a higher risk of contracting tuberculosis compared with metformin.
New recommendations suggest that high risk tuberculosis patients with cough should be screened for pulmonary tuberculosis.
